Is Collegium Pharmaceutical, Inc. (COLL) a Buy, Sell, or Hold?
NASDAQ : COLL
Collegium Pharmaceutical, Inc.
$35.11 USD
-$0.47 (-1.32%)
- Volume
- 7.96K
- Average Volume
- 431.47K
- Market Capitalization
- $1.14B
- P/E Ratio
- 14.81
- Dividend Yield
- 0.00%
- Price Target
- $58.00
- Year High
- $50.79
- Year Low
- $29.70
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $1.71
Company Overview
NASDAQ
Vikram Karnani
Drug Manufacturers - Specialty & Generic
Healthcare
COLL
423
US
USD
Liquidity Metrics
2.59
1.71
1.62
0.62
0.00
Sales & Valuation
$780.57M
1.43
3.61
3.45
10.28
Profitability
$1.73
$62.87M
9.41%
13.59%
26.74%
4.54%
P/E Metrics
14.81
0.21
0.21
Analyst Price Target & Rating
$58.00
$58.00
$58.00
3/5
12 Analysts
-39.47%
Financial Health Scores
1.69
7/9
$310.7M
$1.65B
$1.34B
$271.12M
Key Metrics (TTM)
$1.69B
2.12
2.77
1.71
26.74%
10.51%
6.60%
28.73%
$22.62
147 days
Company Executives
| Name | Title |
|---|---|
| Dean J. Patras | Chief People Officer |
| Thomas Smith FAAFP | Executive Vice President & Chief Medical Officer |
| Ian Karp | Head of Investor Relations |
| Scott Sudduth | EVP & Head of Technical Operations |
| Jane Gonnerman | Executive Vice President of Strategy & Corporate Development |
| Jessica Cotrone | Senior Vice President of Communications & Corporate Affairs |
| David Dieter | Executive Vice President, General Counsel & Corporate Secretary |
| Vikram Karnani | President, Chief Executive Officer & Director |
| Colleen Tupper | Executive Vice President & Chief Financial Officer |
Poll Results
No votes yet today — be the first to share your view!
About Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Stock
Collegium Pharmaceutical, Inc. (COLL) is a specialized pharmaceutical firm dedicated to the development and marketing of medications for pain management. Its diverse product lineup features significant therapies aimed at addressing various pain conditions. A prominent offering is Xtampza ER, an extended-release, oral formulation of oxycodone, specifically engineered with properties to deter abuse. This particular drug is prescribed for patients experiencing severe, persistent pain that necessitates daily, continuous, long-term opioid therapy. The company's portfolio also encompasses Nucynta ER and Nucynta IR, which are extended-release and immediate-release versions of tapentadol, respectively. Founded in 2002, the enterprise initially operated under the name Collegium Pharmaceuticals, Inc ... ., before officially adopting its current identity as Collegium Pharmaceutical, Inc. in October 2003. The company's corporate headquarters are situated in Stoughton, Massachusetts.
Collegium Pharmaceutical: Pain Cash Flows Are Funding An ADHD Re-Rating
2026-08-01 14:12:27
Collegium Pharmaceutical (COLL) is transitioning from a pain-management roll-up to a CNS platform, leveraging stable pain cash flows to fuel ADHD franchise growth. The AZSTARYS acquisition, funded with $350M cash and $300M debt, is expected to deliver $60–70M revenue in 2026 and $50M+ annual synergies within 12 months. COLL's 2026 guidance is $865–895M in revenue and $475–500M adjusted EBITDA, with a 55% margin, reflecting only partial-year AZSTARYS contribution and early synergies.
Collegium to Report Second Quarter 2026 Financial Results on August 6, 2026
2026-07-23 08:00:00
STOUGHTON, Mass., July 23, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading biopharmaceutical company focused on improving the lives of people living with serious and often misunderstood conditions, today announced that it will report second quarter 2026 financial results before the market opens on Thursday August 6, 2026.
Bessemer Group Inc. Acquires 31,800 Shares of Collegium Pharmaceutical, Inc. $COLL
2026-07-22 03:40:43
Bessemer Group Inc. grew its stake in shares of Collegium Pharmaceutical, Inc. (NASDAQ: COLL) by 48.0% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 98,020 shares of the specialty pharmaceutical company's stock after purchasing an additional 31,800 shares during the quarter. Bessemer
DivcoWest Welcomes Collegium Pharmaceutical to One Lincoln
2026-07-20 08:33:00
BOSTON--(BUSINESS WIRE)--DivcoWest, a DivCore Capital company and national commercial real estate investment firm, today announced that Collegium Pharmaceutical, a leading biopharmaceutical company, has signed a lease for 40,288 square feet on floors 11 and 12 at One Lincoln in Boston's Financial District. The 36‑story, 1.1‑million‑square‑foot Class A office tower completed a transformative renewal in 2025 and now serves as a landmark next-generation workplace for world-class established and gr.
Collegium Pharmaceutical Announces New Corporate Headquarters at One Lincoln in Boston
2026-07-20 08:00:00
STOUGHTON, Mass., July 20, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) a leading biopharmaceutical company focused on improving the lives of people living with serious and often misunderstood conditions, today announced plans to relocate its corporate headquarters to One Lincoln in downtown Boston in the first quarter of 2027.
Should Value Investors Buy Collegium Pharmaceutical (COLL) Stock?
2026-07-09 10:41:39
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
4 Defensive Stocks to Take Refuge in as Tech Sell-off Continues
2026-07-08 09:26:10
COLL, IRWD, AMTB and DUK stand out as defensive stock picks as investors rotate from AI-driven tech amid the ongoing sell-off and seek safer sectors.
New Strong Buy Stocks for July 6th
2026-07-06 05:36:06
BBCP, KUBTY, ADM, COLL and W have been added to the Zacks Rank #1 (Strong Buy) List on July 6, 2026.
Frequently Asked Questions
-
What is the current Collegium Pharmaceutical, Inc. (COLL) stock price?
-
Collegium Pharmaceutical, Inc.(NASDAQ:COLL) stock price is $35.11 in the last trading session. During the trading session, COLL stock reached the peak price of $50.787 while $29.7 was the lowest point it dropped to. The percentage change in COLL stock occurred in the recent session was --1.32% while the dollar amount for the price change in COLL stock was -$0.47.
-
COLL's industry and sector of operation?
-
The NASDAQ listed COLL is part of Drug Manufacturers - Specialty & Generic industry that operates in the broader Healthcare sector.
-
Who are the executives of COLL?
-
Dean J. Patras | Chief People Officer
Thomas Smith FAAFP | Executive Vice President & Chief Medical Officer
Ian Karp | Head of Investor Relations
Scott Sudduth | EVP & Head of Technical Operations
Jane Gonnerman | Executive Vice President of Strategy & Corporate Development -
How many employees does COLL have?
-
Number of COLL employees currently stands at 423. COLL operates from 100 Technology Center Drive, Stoughton, MA 02072, US.
-
Link for COLL official website?
-
Official Website of COLL is: https://www.collegiumpharma.com
-
How do I contact COLL?
-
COLL could be contacted at phone #781 713 3699 and can also be accessed through its website. COLL operates from 100 Technology Center Drive, Stoughton, MA 02072, US.
-
How many shares of COLL are traded daily?
-
The average number of COLL shares traded daily for last 3 months was 431.47K.
-
What is the market cap of COLL currently?
-
The market value of COLL currently stands at $1.14B with its latest stock price at $35.11